Cardiovascular

Latest News

Heart examination | Image credit: Ngampol - stock.adobe.com

Elevated Stress Hyperglycemia Ratio Linked to Higher All-Cause Mortality After Cardiovascular Events

By Pearl Steinzor

November 20th 2024

Evidence highlights the predictive value of the stress hyperglycemia ratio for mortality risk in patients with acute myocardial infarction, ischemic stroke, and acute heart failure.

Smoking health risk | Image credit: sorapop - stock.adobe.com

How Smoking Cessation Affects Cardiovascular Disease Risk Over Time

By Pearl Steinzor

November 15th 2024

Stressed female employee | Image Credit: Charlie's - stock.adobe.com

Work-Related Stress Linked to Poor Cardiovascular Health

By Brooke McCormick

November 6th 2024

Doctor holding heart_Pana Studio - stock.adobe.com.jpeg

Evaluating the American Heart Association’s PREVENT Equations: Enhancing CVD Risk Prediction

By Pearl Steinzor

October 24th 2024

Viet Le, PA-C, Intermountain Health

Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery

October 19th 2024

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Hands holding a heart with a heartbeat on it and the words AJMC Insights

Continuing Medical Education

November 21st 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology

November 21st 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

November 21st 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Dr Alex C. Spyropoulos Discusses the Patient-Centered Directions of Rivaroxaban Research

March 28th 2017

Dr Alex C. Spyropoulos Discusses the Patient-Centered Directions of Rivaroxaban Research

According to Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine, research on rivaroxaban to prevent thrombosis is moving from determining efficacy to evaluating patient-centered outcomes in a variety of clinical situations, as evidenced by new studies like EINSTEIN-CHOICE and the MARINER trial.

Dr Jim McDermott Discusses Objectives and Outcomes of CVD-REAL Trial

March 20th 2017

Dr Jim McDermott Discusses Objectives and Outcomes of CVD-REAL Trial

The CVD-REAL study presented at the American College of Cardiology 66th Scientific Session asked whether cardiovascular outcomes seen in the EMPA-REG OUTCOME trial could be seen in a real-world environment, and for the entire class of SGLT2 inhibitors, according to AstraZeneca’s Jim McDermott, PhD, vice president for Medical Affairs, Diabetes.

Dr Janet Wright Outlines Goals and Roadblocks of Million Hearts Initiative

March 20th 2017

Dr Janet Wright Outlines Goals and Roadblocks of Million Hearts Initiative

The Million Hearts initiative launched in 2012 set a lofty goal of preventing 1 million cardiovascular deaths in 5 years, but did not quite achieve that target. According to the program’s executive director, Janet Wright, MD, FACC, Million Hearts will continue to make progress in part due to the solid foundations it has formed in the initial stage.

March 17th 2017

Women Taking Statins Faced Increased Diabetes Risk

The study found a "dose effect" in the elderly women who took statins to treat cholesterol.

March 16th 2017

Seniors Are Living Longer, Thanks to Medicare Part D

The drop in mortality was driven by a significant drop in cardiovascular mortality, the leading cause of death among seniors.

March 11th 2017

Unmet Needs in Cardiovascular Risk Reduction

March 9th 2017

Marijuana Use Linked to High Risk of Heart Failure, Stroke

Christina Mattina

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.

February 15th 2017

In Light of SPRINT, How to Treat Hypertension?

An author in JAMA points out some caveats to a ground-breaking trial.

February 4th 2017

FOURIER Study Finds Repatha Reduces Risk of Cardiovascular Events

Laura Joszt, MA

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March 2017 at the American College of Cardiology 66th Scientific Sessions.

January 31st 2017

AHA Calls for Timing Meals to Lower Cardiovascular Risk

Busy lifestyles are eroding the lines of traditional meal times, and all-day eating is bad for cardiovascular health, the statement says.

January 17th 2017

What's as Bad for the Heart as Obesity? Try Depression

The study found only tobacco use and hypertension were worse on the heart than depression.

January 16th 2017

Safety of Januvia in Oldest Patients With Diabetes Confirmed in Study

The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions.

December 2nd 2016

Jardiance Gets CV Indication for Adults With Type 2 Diabetes

Researchers considered finding a diabetes drug that also produced a cardiovascular benefit to be a "holy grail."

November 21st 2016

Intarcia Submits New Drug Application to FDA for Diabetes Treatment

The matchstick-size pump has been heralded as a game changer in addressing the biggest problem in diabetes care: medication adherence.

November 14th 2016

Could Vectra DA Test Be Used to Predict Cardiovascular Risk?

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.

October 26th 2016

Long-Term Exposure to Pollution Linked to Heart Disease

A new study suggests pollution particles could set into motion events like heart attacks and strokes years before they occur.

October 5th 2016

Fear of Job Loss Increases Risk of Diabetes, Study Finds

While the researchers found a "modest risk" of diabetes associated with job insecurity, they said it pointed to the need for policies that promoted job stability and better wages.

October 3rd 2016

Higher Heart Rate Linked to Increased Mortality, Hospitalization Among African Americans

The Jackson Heart Study continues to yield insights about the nature of cardiovascular disease in minority populations.

September 27th 2016

Therapeutics Issue of Evidence-Based Diabetes Management Takes on Cost, Coverage, and Combinations

Whether it’s the high cost of insulin or the question of when to start combination therapy, the new issue of Evidence-Based Diabetes Management, a publication of The American Journal of Managed Care, covers up-to-the-minute topics in this special issue on therapeutics. Editor-in-chief Robert A. Gabbay, MD, PhD, FACP, leads off this issue featuring voices of providers, pharmaceutical leaders, payers, and patients.

September 23rd 2016

Peer Exchange: As Trials Show CV Benefits in Therapy, Panelists Discuss "Exciting Time" in Diabetes Care

Second of 2 Parts: See Part 1, in Evidence-Based Diabetes Management, coverage of Patient-Centered Diabetes Care 2016.

September 16th 2016

Novo's Semaglutide Reduces CV Risk, but Shows More Retinopathy Complications

Results for Novo Nordisk’s semaglutide were reported today at the European Association for the Study of Diabetes. A filing for FDA approval is expected before the end of the year.

September 14th 2016

Minorities, Southerners in Medicare Less Likely to Take High Blood Pressure Medication

The authors said this is the first study to examine antihypertension nonadherence down to the county level. Recommendations include greater use of combination therapy to reduce pill counts for patients with multiple chronic conditions, and synchronizing pharmacy visits to avoid multiple trips.

August 8th 2016

AstraZeneca Updates Digital Lifestyle Program to Include CV Health

While the online tools makes clear consumers can use it without obligation, the therapy section give patients information on AstraZeneca products.

August 5th 2016

The Financial Impact of Team-Based Care on Primary Care

Thomas E. Kottke, MD, MSPH Michael V. Maciosek, PhD Jacquelyn A. Huebsch, RN, PhD Paul McGinnis, MD Jolleen M. Nichols, RN Emily D. Parker, PhD Juliana O. Tillema, MPA

Although team-based care improved cardiovascular disease risk factors, it had a negative financial impact on a primary care practice.

August 1st 2016

Getting Ready for Bundled Payments in Cardiac Care

Two consultants who help stakeholders in value-based transitions say CMS is serious about an aggressive pace for payment reform.

July 28th 2016

Sanofi's Lixisenatide Approved, Paving Way for OK of Combo Therapy

The approval paves the way for Sanofi's insulin and GLP-1 combination therapy, which is due for final FDA action in August.

July 25th 2016

CMS Proposes Mandatory Bundled Payments for Cardiac Care

This would be the second group of procedures targeted for bundled payments in Medicare. Rules for hip and knee replacements went into effect in April in 67 markets.

July 20th 2016

Patients at High Risk for Cardiovascular Events Not Taking Optimum Statin Doses

Despite evidence and clinical guidelines that support intensive statin use in high-risk patients, very few eligible patients start treatment at recommended levels.

July 18th 2016

Impact of a Physician-Led Point of Care Medication Delivery System on Medication Adherence

Ana Palacio, MD, MPH Jessica Chen, MD Leonardo Tamariz, MD, MPH Sylvia D. Garay, MD Hua Li, PhD Olveen Carrasquillo, MD, MPH

A point of care medication delivery system improves medication adherence to cardiovascular medications without increasing costs.

July 5th 2016

FDA Panel Narrowly OKs Empagliflozin CV Benefit Claim

If the full FDA accepts the panel's narrow recommendation, the type 2 diabetes therapy could enjoy a preferred status above its rivals in the SGLT2 market.

...

12 13 14 15 16 17 18 19 20

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions